{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T03:07:33Z","timestamp":1783480053824,"version":"3.55.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jbo.2022.100423","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T14:19:30Z","timestamp":1647526770000},"page":"100423","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach"],"prefix":"10.1016","volume":"34","author":[{"given":"Dionna","family":"Jacobson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Cadieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celestia S.","family":"Higano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basia A.","family":"Bachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Rehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison T.","family":"Stopeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossam","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jbo.2022.100423_b0005","first-page":"321","article-title":"Bone metastases: an overview","volume":"11","author":"Macedo","year":"2017","journal-title":"Oncol. Rev."},{"issue":"1","key":"10.1016\/j.jbo.2022.100423_b0010","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12885-017-3922-0","article-title":"Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States","volume":"18","author":"Hernandez","year":"2018","journal-title":"BMC Cancer"},{"issue":"12","key":"10.1016\/j.jbo.2022.100423_b0015","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO Clinical Practice Guidelines,","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbo.2022.100423_b0020","first-page":"87","article-title":"Estimated number of prevalent cases of metastatic bone disease in the US adult population","volume":"4","author":"Li","year":"2012","journal-title":"Clin. Epidemiol."},{"issue":"7","key":"10.1016\/j.jbo.2022.100423_b0025","doi-asserted-by":"crossref","first-page":"482","DOI":"10.21037\/atm.2020.03.55","article-title":"Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study","volume":"8","author":"Huang","year":"2020","journal-title":"Ann. Transl. Med."},{"issue":"6","key":"10.1016\/j.jbo.2022.100423_b0030","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1080\/13696998.2018.1457531","article-title":"Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database","volume":"21","author":"Bhowmik","year":"2018","journal-title":"J. Med. Econ."},{"issue":"2","key":"10.1016\/j.jbo.2022.100423_b0035","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40273-013-0121-y","article-title":"The economic burden of skeletal-related events among elderly men with metastatic prostate cancer","volume":"32","author":"Jayasekera","year":"2014","journal-title":"PharmacoEconomics"},{"issue":"3","key":"10.1016\/j.jbo.2022.100423_b0040","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2015-0327","article-title":"The clinical and economic impacts of skeletal-related events among Medicare enrollees with prostate cancer metastatic to bone","volume":"21","author":"McDougall","year":"2016","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.jbo.2022.100423_b0045","article-title":"Role of bone targeting agents in the prevention of bone metastases from breast cancer","volume":"21","author":"D'Oronzo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"35","key":"10.1016\/j.jbo.2022.100423_b0050","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.2017.75.4614","article-title":"Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update","volume":"35","author":"Poznak","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.jbo.2022.100423_b0055","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1002\/cam4.914","article-title":"Risk of skeletal related events among elderly prostate cancer patients by site of metastasis at diagnosis","volume":"5","author":"Hussain","year":"2016","journal-title":"Cancer Med"},{"issue":"9","key":"10.1016\/j.jbo.2022.100423_b0060","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/cncr.30505","article-title":"Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer","volume":"123","author":"Klaassen","year":"2017","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.jbo.2022.100423_b0065","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10549-020-05712-4","article-title":"Risk factors for skeletal-related events in patients with bone metastasis from breast cancer undergoing treatment with zoledronate","volume":"182","author":"Miyashita","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.jbo.2022.100423_b0070","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1159\/000489218","article-title":"Clinical features and risk factors of skeletal-related events in genitourinary cancer patients with bone metastasis: a retrospective analysis of prostate cancer, renal cell carcinoma, and urothelial carcinoma","volume":"95","author":"Owari","year":"2018","journal-title":"Oncology"},{"issue":"2","key":"10.1016\/j.jbo.2022.100423_b0075","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.lungcan.2008.10.026","article-title":"Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapy","volume":"65","author":"Sekine","year":"2009","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.jbo.2022.100423_b0080","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s13277-015-3907-z","article-title":"Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases","volume":"37","author":"Ulas","year":"2016","journal-title":"Tumour Biol."},{"key":"10.1016\/j.jbo.2022.100423_b0085","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jbo.2018.01.004","article-title":"Incidence, risk factors and prognostic characteristics of bone metastases and skeletal-related events (SREs) in breast cancer patients: A systematic review of the real world data","volume":"11","author":"Zhang","year":"2018","journal-title":"J. Bone Oncol."},{"issue":"9768","key":"10.1016\/j.jbo.2022.100423_b0090","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jbo.2022.100423_b0095","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdu519","article-title":"Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events","volume":"26","author":"Smith","year":"2015","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.jbo.2022.100423_b0100","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.eururo.2014.10.001","article-title":"Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer","volume":"68","author":"Fizazi","year":"2015","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.jbo.2022.100423_b0105","first-page":"447","article-title":"Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer","volume":"24","author":"Stopeck","year":"2016","journal-title":"Support. Care Cancer"},{"issue":"16","key":"10.1016\/j.jbo.2022.100423_b0110","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.jbo.2022.100423_b0115","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1517\/17425255.2015.1000860","article-title":"Denosumab for the treatment of osteoporosis","volume":"11","author":"Zaheer","year":"2015","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"3","key":"10.1016\/j.jbo.2022.100423_b0120","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/03007995.2018.1558849","article-title":"Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in the United States","volume":"35","author":"Henry","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"issue":"8","key":"10.1016\/j.jbo.2022.100423_b0125","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1002\/cam4.3776","article-title":"Machine learning for the prediction of bone metastasis in patients with newly diagnosed thyroid cancer","volume":"10","author":"Liu","year":"2021","journal-title":"Cancer Med."},{"issue":"6","key":"10.1016\/j.jbo.2022.100423_b0130","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/jor.24660","article-title":"Fracture risk assessment and clinical decision making for patients with metastatic bone disease","volume":"38","author":"Damron","year":"2020","journal-title":"J. Orthop. Res."},{"key":"10.1016\/j.jbo.2022.100423_b0135","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12874-015-0047-5","article-title":"Measurement of skeletal related events in SEER-Medicare: a comparison of claims-based methods","volume":"15","author":"Aly","year":"2015","journal-title":"BMC Med. Res. Method."},{"key":"10.1016\/j.jbo.2022.100423_b0140","series-title":"Proceedings of the ACM SIGKDD International Conference on Knowledge Discovery and Data Mining","first-page":"785","article-title":"XGBoost: A Scalable Tree Boosting System","author":"Chen","year":"2016"},{"issue":"1","key":"10.1016\/j.jbo.2022.100423_b0145","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1038\/s41598-021-83828-3","article-title":"Machine learning approaches for the prediction of bone mineral density by using genomic and phenotypic data of 5130 older men","volume":"11","author":"Wu","year":"2021","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.jbo.2022.100423_b0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237213","article-title":"Bone metastasis classification using whole body images from prostate cancer patients based on convolutional neural networks application","volume":"15","author":"Papandrianos","year":"2020","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.jbo.2022.100423_b0155","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13059-019-1689-0","article-title":"Machine learning and complex biological data","volume":"20","author":"Xu","year":"2019","journal-title":"Genome Biol."},{"issue":"4","key":"10.1016\/j.jbo.2022.100423_b0160","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1634\/theoncologist.2015-0377","article-title":"Risk factors for developing skeletal-related events in breast cancer patients with bone metastases undergoing treatment with bone-modifying agents","volume":"21","author":"Tanaka","year":"2016","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.jbo.2022.100423_b0165","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.jbo.2022.100423_b0170","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.jbo.2022.100423_b0175","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.clbc.2011.03.015","article-title":"Treatment persistence with monthly zoledronic acid is associated with lower risk and frequency of skeletal complications in patients with breast cancer and bone metastasis","volume":"11","author":"Hatoum","year":"2011","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"10.1016\/j.jbo.2022.100423_b0180","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1185\/03007995.2015.1105795","article-title":"A comprehensive review of denosumab for bone metastasis in patients with solid tumors","volume":"32","author":"G\u00fcl","year":"2016","journal-title":"Curr. Med. Res. Opin."},{"issue":"3","key":"10.1016\/j.jbo.2022.100423_b0185","first-page":"679","article-title":"Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors","volume":"22","author":"Henry","year":"2014","journal-title":"Support. Care Cancer"},{"issue":"5","key":"10.1016\/j.jbo.2022.100423_b0190","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.3747\/co.22.2380","article-title":"Physician preferences for bone metastasis drug therapy in Canada","volume":"22","author":"Arellano","year":"2015","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.jbo.2022.100423_b0195","first-page":"97","article-title":"Hospital visits among women with skeletal-related events secondary to breast cancer and bone metastases: a nationwide population-based cohort study in Denmark","volume":"5","author":"Svendsen","year":"2013","journal-title":"Clin. Epidemiol."},{"issue":"7","key":"10.1016\/j.jbo.2022.100423_b0200","first-page":"341","article-title":"Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice","volume":"4","author":"Delea","year":"2006","journal-title":"J. Support. Oncol."},{"issue":"6","key":"10.1016\/j.jbo.2022.100423_b0205","first-page":"755","article-title":"The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain","volume":"19","author":"Pockett","year":"2010","journal-title":"Eur. J. Cancer Care"},{"key":"10.1016\/j.jbo.2022.100423_b0210","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3332\/ecancer.2017.715","article-title":"Bone metastasis risk factors in breast cancer","volume":"11","author":"Pulido","year":"2017","journal-title":"Ecancermedicalscience"},{"issue":"1","key":"10.1016\/j.jbo.2022.100423_b0215","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4103\/0971-5851.176980","article-title":"Prostate cancer is not breast cancer","volume":"37","author":"Venniyoor","year":"2016","journal-title":"Indian J. Med. Paediatr. Oncol."},{"key":"10.1016\/j.jbo.2022.100423_b0220","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.canep.2019.05.013","article-title":"Incidence of skeletal-related events in patients with breast or prostate cancer-induced bone metastasis or multiple myeloma: A 12-year longitudinal nationwide healthcare database study","volume":"61","author":"Baek","year":"2019","journal-title":"Cancer Epidemiol."},{"key":"10.1016\/j.jbo.2022.100423_b0225","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40880-016-0102-6","article-title":"A multicenter, retrospective epidemiologic survey of the clinical features and management of bone metastatic disease in China","volume":"35","author":"Yang","year":"2016","journal-title":"Chin J Cancer"},{"issue":"1","key":"10.1016\/j.jbo.2022.100423_b0230","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrc1528","article-title":"Osteoblasts in prostate cancer metastasis to bone","volume":"5","author":"Logothetis","year":"2005","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.jbo.2022.100423_b0235","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3390\/cancers10060182","article-title":"Cancer metastases to bone: concepts, mechanisms, and interactions with bone osteoblasts","volume":"10","author":"Shupp","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.jbo.2022.100423_b0240","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.3390\/ijms20102587","article-title":"Prostate cancer and bone metastases: the underlying mechanisms","volume":"20","author":"Wong","year":"2019","journal-title":"Int. J. Mol. Sci."}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137422000136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137422000136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:19:07Z","timestamp":1761941947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137422000136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":48,"alternative-id":["S2212137422000136"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2022.100423","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2022.100423","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100423"}}